Diana F Clarke, Assistant Professor of Paediatrics at Boston University School of Medicine and Lead Investigator of the ...

Clinical trials are becoming increasingly complex. In a 2023 survey, 70% of investigative site staff said conducting studies ...

Reducing variation, preventing complications, supporting care ...

Hi, this project/product/partnership is going live next week – can you do some comms?’ ...

The introduction of oral GLP-1 medicines, alongside growing awareness of injectable treatments such as Wegovy and Mounjaro, ...

Cell Therapies has manufactured and released the first clinical dose for the KOALA trial, marking the start of a ...

The UK approval of once-daily oral Wegovy is a significant moment for obesity treatment. For the first time, patients can ...

This month's mag takes the relentless tittle-tattle from 'influencers' about GLP-1 before scrutinizing, deconstructing and ...

IMAAVY has become the first FDA‑approved therapy for warm autoimmune haemolytic anaemia, offering a targeted approach ...

Nxera Pharma has announced that its partner Neurocrine Biosciences has received FDA IND acceptance for a phase 2 study of NBI‑1117567 for Alzheimer’s cognition. Nxera will rec ...

GSK has announced that the US FDA has accepted for priority review a supplemental Biologics License Application for Jemperli ...

A July 2026 Leerink Partners report named Carterra a core enabling technology in the growing Lab‑in‑the‑Loop market. The ...